Sign up Australia
Proactive Investors - Run By Investors For Investors

ImmunoPrecise Antibodies set to buy ModiQuest in C$10.5mln deal

The deal allows IPA to become a single source provider of services across the full antibody discovery value chain, the firm told investors.
ImmunoPrecise Antibodies set to buy ModiQuest in C$10.5mln deal
IPA develops antibodies to support research and development programs

ImmunoPrecise Antibodies Ltd (CVE:IPA, OTC PINK:IPATF) is set to buy ModiQuest Research BV in a C$10.57mln deal, which bolsters its global acquisition strategy and will add to both revenue and earnings, it said.

It allows IPA to become a single source provider of services across the full antibody discovery value chain, it told investors.

In simple terms, IPA develops antibodies to support research and development programs at pharmaceutical and biotechnology companies, as well as academic research labs.

Targetting antigens..

Antibodies  can target molecules, or antigens. They are produced by the immune  system to help stop intruders from harming the body.

This acquisition will enhance the firm's capacity for generating human antibodies, it said.

Privately-held ModiQuest, based in the Netherlands, can generate very large panels of monoclonal antibodies from various backgrounds including mouse, rat, rabbit, chicken, llama and human

ModiQuest serves clients in Europe, the US, Asia and Russia and during 2016, it posted revenues of €2,009,374 (CAD $3,037,249) and earnings of €671,799 (CAD $1,015,451).

"In acquiring ModiQuest Research B.V, IPA becomes a leading integrated antibody solutions company with global reach," said Dr James Kuo,  chairman and interim president of the company.

A binding letter of intent..

Under a binding letter of intent, the  parties have agreed to negotiate a definitive agreement, whereby IPA will acquire all ModiQuest shares for C$10.57mln, of which C$3.775mln will be paid in cash on closing.

Also, C$3.775mln  will be satisfied by issuing around 6.6mln shares on closing, and C$2mln in deferred payments over three years.

The deferred payments will be made in three equal installments of cash and equity totaling (C$$1,006,665) on each anniversary date following closing of the transaction.

The parties will be entitled to carry out due diligence of each other until February 15 next year, and if satisfied, will  enter a definitive agreement by February 28.

Shares added over 5% to C$0.60 each..

View full IPA profile View Profile

Immunoprecise Antibodies Ltd Timeline

Related Articles

3d rendering of an antibody
July 24 2018
It is teaming up with Bach BioSciences, a company commercialising the research of William Bachovchin, a professor at Tufts University School of Medicine, Boston
car-t cells definition
September 24 2018
The phase I clinical study will evaluate the safety of MaxCyte's MCY-M11 chimeric antigen receptor in people with relapsed or difficult-to-treat ovarian cancer and peritoneal mesothelioma
1528098797_Biotech-lab.jpg
June 05 2018
While tricky, the last year has seen Abzena increase its customer engagement with its integrated discovery, development and manufacturing service offering

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use